Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

Several other research firms have also weighed in on CMPX. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $5.00 to $4.00 in a report on Friday, November 15th. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, September 16th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $1.86 on Wednesday. The business’s 50-day moving average is $1.57 and its two-hundred day moving average is $1.44. The company has a market capitalization of $255.92 million, a P/E ratio of -5.03 and a beta of 0.92. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Analysts forecast that Compass Therapeutics will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Rovin Capital UT ADV acquired a new stake in shares of Compass Therapeutics in the third quarter worth approximately $25,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth $30,000. XTX Topco Ltd acquired a new stake in Compass Therapeutics during the 3rd quarter worth $37,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics in the second quarter valued at about $41,000. Finally, SG Americas Securities LLC raised its position in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.